Header Logo

Connection

Theodore Pincus to Antirheumatic Agents

Back to Details
This is a "connection" page, showing publications Theodore Pincus has written about Antirheumatic Agents.
Theodore Pincus
Connection Strength
11.385
Antirheumatic Agents
  1. Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. J Rheumatol. 2019 01; 46(1):27-30.
    View in: PubMed
    Score: 0.614
  2. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. J Rheumatol. 2016 07; 43(7):1285-91.
    View in: PubMed
    Score: 0.516
  3. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3.
    View in: PubMed
    Score: 0.433
  4. Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria? J Rheumatol. 2013 Sep; 40(9):1469-74.
    View in: PubMed
    Score: 0.430
  5. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(2):117-20.
    View in: PubMed
    Score: 0.411
  6. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
    View in: PubMed
    Score: 0.411
  7. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S20-8.
    View in: PubMed
    Score: 0.411
  8. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
    View in: PubMed
    Score: 0.411
  9. Treat-to-target: not as simple as it appears. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S10-20.
    View in: PubMed
    Score: 0.405
  10. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012 Aug 21; 157(4):299; author reply 300.
    View in: PubMed
    Score: 0.401
  11. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol. 2011 Dec; 38(12):2565-71.
    View in: PubMed
    Score: 0.380
  12. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1142-9.
    View in: PubMed
    Score: 0.372
  13. Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care. Bull NYU Hosp Jt Dis. 2011; 69(2):104-10.
    View in: PubMed
    Score: 0.358
  14. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2010 Sep; 49(9):1795-6; author reply 1796-7.
    View in: PubMed
    Score: 0.343
  15. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov; 35(4):723-9, vi.
    View in: PubMed
    Score: 0.330
  16. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009 Nov; 35(4):829-42, x-xi.
    View in: PubMed
    Score: 0.330
  17. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009 Aug 08; 374(9688):430-2.
    View in: PubMed
    Score: 0.325
  18. Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol. 2008 Jun; 4(6):294-5.
    View in: PubMed
    Score: 0.298
  19. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol. 2008; 18(3):228-39.
    View in: PubMed
    Score: 0.297
  20. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
    View in: PubMed
    Score: 0.288
  21. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb; 34(2):250-2.
    View in: PubMed
    Score: 0.273
  22. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
    View in: PubMed
    Score: 0.269
  23. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 2005 Dec; 52(12):4044-5; author reply 4045-7.
    View in: PubMed
    Score: 0.251
  24. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005 Apr; 52(4):1031-6.
    View in: PubMed
    Score: 0.240
  25. Add-on or step-up trials in rheumatoid arthritis: comment on the article by Boers. Arthritis Rheum. 2004 Apr; 50(4):1351; author reply 1351-2.
    View in: PubMed
    Score: 0.224
  26. Guidelines for monitoring of methotrexate therapy: "evidence-based medicine" outside of clinical trials. Arthritis Rheum. 2003 Oct; 48(10):2706-9.
    View in: PubMed
    Score: 0.216
  27. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol. 2003 Jun; 30(6):1138-46.
    View in: PubMed
    Score: 0.211
  28. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003 Feb; 48(2):313-8.
    View in: PubMed
    Score: 0.207
  29. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol. 2002 Dec; 29(12):2521-4.
    View in: PubMed
    Score: 0.204
  30. Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018 08; 70(8):1198-1205.
    View in: PubMed
    Score: 0.150
  31. Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis Rheumatol. 2017 07; 69(7):1374-1380.
    View in: PubMed
    Score: 0.139
  32. Information technology in rheumatology. Clin Exp Rheumatol. 2016 Sep-Oct; 34(5 Suppl 101):1.
    View in: PubMed
    Score: 0.134
  33. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford). 2013 Oct; 52(10):1890-7.
    View in: PubMed
    Score: 0.107
  34. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol. 2013 Apr; 40(4):386-93.
    View in: PubMed
    Score: 0.103
  35. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
    View in: PubMed
    Score: 0.090
  36. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
    View in: PubMed
    Score: 0.090
  37. In the clinic. Rheumatoid arthritis. Ann Intern Med. 2010 Jul 06; 153(1):ITC1-1-ITC1-15; quiz ITC1-16.
    View in: PubMed
    Score: 0.086
  38. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009 Nov; 35(4):773-8, viii.
    View in: PubMed
    Score: 0.082
  39. Management of associated rheumatoid arthritis and fibromyalgia. J Rheumatol. 2009 Sep; 36(9):2123-4; discussion 2124-5.
    View in: PubMed
    Score: 0.082
  40. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis. 2009; 67(3):254-66.
    View in: PubMed
    Score: 0.078
  41. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008 Nov; 35(11):2136-47.
    View in: PubMed
    Score: 0.076
  42. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008; 10(2):R30.
    View in: PubMed
    Score: 0.074
  43. Shouldn't standard rheumatology clinical care be evidence-based rather than eminence-based, eloquence-based, or elegance-based? J Rheumatol. 2007 Jan; 34(1):1-4.
    View in: PubMed
    Score: 0.068
  44. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
    View in: PubMed
    Score: 0.067
  45. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005 Dec; 52(12):3873-9.
    View in: PubMed
    Score: 0.063
  46. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009; 11(1):R7.
    View in: PubMed
    Score: 0.020
  47. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007 Nov; 66(11):1491-6.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.